Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: Implications for schizophrenia

Journal of Chemical Neuroanatomy

Volumn 36, Issue 2, 2008, Pages 71-76

  Zavitsanou, Katerina ^a,b   Nguyen, Vu ^a   Newell, Kelly ^b,c   Ballantyne, Patrice ^a   Huang, Xu Feng ^b,c  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Amygdala; Autoradiography; Hippocampus; Limbic; Phencyclidine; Receptors; Schizophrenia

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; DIZOCILPINE; GLUTAMIC ACID; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC RECEPTOR; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID; PHENCYCLIDINE; PIRENZEPINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; HIPPOCAMPUS; NONHUMAN; OUTCOME ASSESSMENT; PARIETAL LOBE; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SCHIZOPHRENIA;

AMYGDALA; ANIMALS; CEREBRAL CORTEX; DENTATE GYRUS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLUTAMIC ACID; HIPPOCAMPUS; LIMBIC SYSTEM; MUSCARINIC ANTAGONISTS; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR AGGREGATION; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TIME FACTORS;

EID: 49549086605     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2008.06.004     Document Type: Article

References (39)

1. Abe S., Suzuki T., Ito T., et al. Effects of single and repeated phencyclidine administration on the expression of metabotropic glutamate receptor subtype mRNAs in rat brain. Neuropsychopharmacology 25 (2001) 173-184
2. Bakshi V., and Geyer M. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 18 20 (1998) 8394-8401
3. Corso T., Sesma M., Tenkova T., et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752 1-2 (1997) 1-14
4. Frederick D., Gillam M., Allen R., et al. Acute behavioral-effects of phencyclidine on rhesus-monkey performance in an operant test battery. Pharmacol. Biochem. Behav. 52 4 (1995) 789-797
5. Gao X., Sakai K., Roberts R., et al. Ionotropic glutamate receptors and expression of NMDA receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiat. 157 7 (2000) 1141-1149
6. Gao X., Shirakawa O., Du F., et al. Delayed regional metabolic actions of phencyclidine. Eur. J. Pharmacol. 241 1 (1993) 7-15
7. Gao X., and Tamminga C. Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48-hour time course. Synapse 23 4 (1996) 274-279
8. Giovannini M., Mutolo D., Bianchi L., et al. NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: a microdialysis study. J. Neurosci. 15 (1994) 1358-1365
9. Harrison P., Kerwin R., and McLaughlin D. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 337 (1991) 450-452
10. Hori T., Subramaniam S., Srivastava L., et al. Behavioural and neurochemical alterations following repeated phencyclidine administration in rats with neonatal ventral hippocampal lesions. Neuropharmacology 39 (2000) 2478-2491
11. Hulshoff Pol H., Schnack H., Mandl R., et al. Focal gray matter density changes in schizophrenia. Arch. Gen. Psychiat. 58 (2001) 1118-1125
12. Hutson P., and Hogg J. Effects of and interactions between antagonists for different sites on the NMDA receptor complex on hippocampal and striatal acetylcholine efflux in vivo. Eur. J. Pharmacol. 295 (1996) 45-52
13. Javitt D., and Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiat. 46 (1991) 1301-1309
14. Jentsch J., and Roth R. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-224
15. Kerwin R., Patel S., and Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain postmortem. Neuroscience 39 (1990) 25-32
16. Kosaka H., Omori M., Murata T., et al. Differential amygdala response during facial recognition in patients with schizophrenia: an f MRI study. Schizophr. Res. 57 (2002) 87-95
17. Krystal J., Karper L., Seibyl J., et al. Subanesthetic effects of the noncompetitive NMDA receptor antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiat. 51 (1994) 199-214
18. Maayani S., Weinstein H., Benzvi N., et al. Psychomimetics as anticholinergic agents. I. 1-Cyclohexylpiperdine derivatives: anticholinesterase and antagonistic activity to acetylcholine. Biochem. Pharmacol. 23 (1974) 1263-1281
19. Moghaddam B., Adams B., Verma A., et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 8 (1997) 2921-2927
20. Morgan C., Riccelli M., Maitland C., et al. Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend. 75 3 (2004) 301-308
21. Morris B., Cochran S., and Pratt J. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5 (2005) 101-106
22. Murray T., and Cheney D. The effect of phencyclidine on the turnover rate of acetylcholine in various regions of rat brain. J. Pharmacol. Exp. Ther. 217 (1981) 733-737
23. Newell K.A., Zavitsanou K., and Huang X.F. Opposing short and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. J. Neurosci. Res. 85 (2007) 1358-1363
24. Newell K.A., Zavitsanou K., and Huang X.F. Short and long-term changes in NMDA receptor binding in mouse brain following chronic phencyclidine treatment. J. Neural Transm. 114 (2007) 995-1001
25. Nielsen E.O., Drejer J., Cha J.-H.J., Young A.B., and Honore T. Autoradiographic characterization and localization of quisqualate binding sites in rat brain using the antagonist [3H]6-cyano-7-nitroquinoxaline-2,3-dione-comparison with (R,S)-[3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid binding sites. J. Neurochem. 54 (1990) 686-695
26. Olney J., Labruyere J., and Farber N. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. J. Psychiat. Res. 33 (1999) 523-533
27. Olney J., Newcomer J., and Price M. NMDA receptor hypofunction model of schizophrenia. Science 244 (1989) 1360-1362
28. Paster Z., Maayani S., Weinstein H., et al. Cholinolytic action of phencyclidine derivatives. Eur. J. Pharmacol. 25 (1974) 270-274
29. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
30. Piggott M., Owens J., O'Brien J., Paling S., Wyper D., Fenwick J., Johnson M., Perry R., and Perry E. Comparative distribution of binding of the muscarinic receptor ligands pirenzipine AF-DX 384 (R,R)-I-QNQ and (R,S)-I)QNB to human brain. J. Chem. Neuroanat. 24 (2002) 211-223
31. Shayegan D., and Stahl S. Emotion processing, the amygdale, and outcome in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiat. 29 (2005) 840-845
32. Subramanian S., and McGonigle P. Quantitative autoradiographic characterization of the binding of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine([3H]MK-801) in rat brain: regional effects of polyamines. J. Pharmacol. Exp. Ther. 256 (1991) 811-819
33. Tamminga C., Lahti A., Medoff D., et al. Evaluating glutamatergic transmission in schizophrenia. Ann. NY Acad. Sci. 1003 (2003) 113-118
34. Traub M., Reches A., Wagner H.R., and Fahn S. Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade. Neurosci. Lett. 70 (1986) 245-249
35. Weinstein H., Maayani S., Srebrenik S., et al. Psychotomimetic drugs as anticholinergic agents. II. Quantum-mechanical study on molecular interaction potential of 1-cyclohexylpiperdine derivatives with the cholinergic receptors. Mol. Pharmacol. 9 6 (1973) 820-834
36. Wozniak D., BrosnanWatters G., Nardi A., et al. MK-801 neurotoxicity in male mice: histologic effects and chronic impairment in spatial learning. Brain Res. 707 2 (1996) 165-179
37. Wright I., Ellison Z., Sharma T., et al. Mapping of grey matter changes in schizophrenia. Schizophr. Res. 35 (1999) 1-14
38. Zavitsanou K., Katsifis A., Mattner F., et al. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder and major depression disorder. Neuropsychopharmacology 29 (2004) 619-625
39. Zavitsanou K., Ward P., and Huang X.F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex of schizophrenia. Neuropsychopharmacology 27 (2002) 826-833